Business Wire

MA-ICURE-PHARMACEUTICAL

16.11.2021 15:03:14 CET | Business Wire | Press release

Share
Icure Acquires Drug Product Approval for World’s First Donepezil Patch for Treating Dementia of the Alzheimer Type in Korea

Icure Pharmaceutical Inc. (KOSDAQ: 175250), a biopharmaceutical company in Korea, announced today that its donepezil patch, a treatment of Alzheimer’s-type dementia, received a drug product approval from the Ministry of Food and Drug Safety of Korea.

The drug product approval process took 7 months after it filed an application in April 2021. With the approval, Icure marks the first commercialization of the donepezil patch in the world.

Donepezil is a current typical treatment that has been widely prescribed for the longest period for Alzheimer’s disease patients in severity ranging from mild to moderate and severe ones among FDA-approved Alzheimer's treatments. Due to difficulty in the development of its formulations, donepezil has been commercialized for only oral administration to date.

With successful completion of a Phase III clinical trial for the first time in the world, the donepezil patch of Icure is expected to significantly improve the quality of life of patients with Alzheimer’s-type dementia and their caregivers by enhancing the convenience in its use from orally taking once daily to putting a patch on skin twice a week.

With nearly 400 mild and moderate dementia patients in Korea, Taiwan, Australia and Malaysia, Icure successfully conducted a Phase III clinical study for its donepezil patch. Specifically, the study demonstrated noninferiority compared to oral donepezil in Alzheimer's disease assessment scale cognitive subscale (ADAS-cog), a typical standard tool for evaluating abilities of memory, language, reorganization, action and orientation in patients with mild and moderate Alzheimer’s-type dementia.

“Based on outstanding efficacy and marketability of donepezil along with our technological prowess, we expect our donepezil patch will sufficiently take over the market of donepezil oral products as we have seen a high conversion rate of rivastigmine patches in the past,” said CEO YoungKweon Choi, Ph.D. of Icure, who led donepezil patch development. “We reported results of the Phase III clinical trial of donepezil patch at the Conference on Clinical Trials of Alzheimer’s Disease (CTAD) that was held on November 9~12, 2021 in Boston, Massachusetts.” He attended the CTAD Conference to present the results of the clinical study while making consultations on potential global transactions.

Now that its donepezil patch received FDA approval for Phase I clinical trial as an investigational new drug in April 2021, Icure will start to administer it to patients in the latter part of 2022. The company expects to begin in 2025 to provide the donepezil patch in the global market by reducing the period of clinical trials through the 505(b)2 clinical study track. Today, the global dementia treatments market is estimated to reach around USD 3 billion, and it is anticipated to increase to roughly USD 5 billion by 2024 as the world transforms into an aging society. Icure plans to expand the global business of transdermal drug delivery system (TDDS) as its production facilities in Wanju, Korea obtained the cGMP certification.

Starting with the donepezil patch, Icure diversifies pipelines by developing a variety of DDS-based incrementally modified drugs and new drugs. Following the donepezil patch, the company is developing a pramipexole patch that will be used for treating Parkinson’s disease. And Icure BNP, a subsidiary of Icure, is currently developing oral liraglutide peptide formulation from injectable liraglutide peptide product that is being used for treating diabetes and obesity while accelerating the development of microneedles and lipid-based nanoparticle (LNP) drugs through CuRsuS Bio and EBA BIO. In addition, Icure is also in the development of the world’s first oral peptide-based anticancer drug and a new drug based on PROTAC through oneCureGen and Dandi Cure, attracting attention on the potentiality of growing into a global pharmaceutical company by developing varied DDS-based new drugs.

For more information on Icure Pharmaceutical Inc., visit https://icure.co.kr .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nordson EFD Launches PICO Pµlse XP HV Jetting System to Meet Assembly Market Demand for Dispensing High-Viscosity Materials9.11.2026 16:00:00 CET | Press release

Dispensing Innovation delivers Precise Performance, Ease of Use and Automation Integration Nordson EFD,a Nordson company (NASDAQ: NDSN), today announced the launch of its PICO Pµlse® XP HV jetting system designed for extremely precise (XP) assembly applications utilizing high-viscosity (HV) materials like thick silicones, greases, and UV-cure adhesives. New formulations are rapidly entering the industrial marketplace due to evolutionary new product development across multiple industries including electronics, medical, and automotive. Nordson leveraged its core competencies and time-tested structural architecture to innovate the piezoelectric jetting system for non-contact precision dispensing of this emerging genre of viscous materials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921406991/en/ Caption 1: Engineered for performance, the PICO Pμlse XP HV jetting system excels in demanding applications, such as optical bo

Tashkent Makes History with Central Asia’s First Golden Globes Gala9.11.2026 14:42:00 CET | Press release

Two-time Academy Award winner Adrien Brody joins leading cultural figures as the inaugural Golden Globes Silk Road Tribute Gala brings the awards to the region for the first time Tashkent hosted the inaugural Golden Globes Silk Road Tribute Gala, bringing together internationally recognised actors, filmmakers and cultural figures from Central Asia, the Caucasus and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109918777/en/ Tashkent Makes History with Central Asia’s First Golden Globes Gala (Photo credit: © Organising Committee of the Golden Globes Silk Road Tashkent) Guests of honour included Otabek Umarov, First Deputy Chairman of the National Olympic Committee of Uzbekistan, Vice President of the Olympic Council of Asia and Member of the FIA Senate, and Shakhnoza Mirziyoyeva, First Deputy Director of the National Agency for Social Protection, First Deputy Chairman of the National Paralympic Committee of Uzbeki

Latifa bint Mohammed Inaugurates ISEA20269.11.2026 14:30:00 CET | Press release

Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture and Arts Authority, inaugurated the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), held under the theme ‘ELYAH: Constellating Place, Data, and Identity.’ Bringing together artists, researchers and innovators from around the world, the symposium, in its largest-ever edition, explores how art, science and technology can expand creative expression, deepen cultural understanding, and shape the future of electronic and emerging art. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109319593/en/ Burj Khalifa lights up to celebrate the opening of ISEA2026 Dubai (Photo: AETOSWire) Her Highness marked the inauguration by launching the interactive ELYAH show at ARTE MUSEUM Dubai. Inspired by Dubai’s celestial heritage, the experience combined light, music, performance and digital technology to explore the relations

Muslim World League’s “Minhaj” App Participates in Hajj Conference and Exhibition 2026 in Jeddah9.11.2026 14:04:00 CET | Press release

The “Minhaj” app, developed by the Muslim World League (MWL), is participating in the sixth edition of the Hajj Conference and Exhibition 2026, which commenced today in Jeddah under the patronage of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud (may Allah protect him). Organized by the Ministry of Hajj and Umrah in cooperation with the Pilgrim Experience Program, one of the programs of Saudi Vision 2030, the event is being held from November 8 to 11 at the Jeddah Superdome under the theme “From Makkah to the World.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109411972/en/ The pavilion of the Muslim World League (MWL) at the sixth edition of the Hajj Conference and Exhibition 2026 in Jeddah, Saudi Arabia. (Photo: AETOSWire) Minhaj’s participation in this international event aims to introduce its integrated Islamic digital ecosystem, launched from Makkah to serve Muslims worldwide. The app off

CAIRDAC Adds Operational Expertise to Its Board of Directors With the Appointment of Rinda Sama9.11.2026 13:44:00 CET | Press release

CAIRDAC, SA, a pre-revenue-stage medtech company developing ALPS™, a leadless, self-powered cardiac pacing system, today announced the appointment of Mr. Rinda Sama to its Board of Directors. His appointment adds deep manufacturing, quality and operational experience to the Board and follows the recent appointment of Raymond W. Cohen as Chairman. “Mr. Sama’s extensive experience in manufacturing, quality systems and operational scale-up for complex implantable devices will be extremely valuable to our Company as we prepare for clinical evaluation and the next stages of development,” said Edouard Fonck, Chief Executive Officer of CAIRDAC. Mr. Sama currently serves as CEO of Spiro Medical, a company focused on treating asthma employing a proprietary neuromodulation system. He previously served as Chief Operating Officer of publicly traded Axonics, Inc. where he was accountable for manufacturing and quality and the operational infrastructure that supported the company’s commercial growth.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye